Deck
Molina collects monthly capitation from state Medicaid agencies and CMS, takes the financial risk of paying providers, and earns a thin regulated spread serving 5.5 million low-income members across 21 states.
Operating margin halved in a single year — and the cycle has not yet confirmed it comes back.
- The collapse. Operating margin fell from 4.2% to 1.7% in FY2025; adjusted EPS dropped from $22.65 to $11.03; FY2026 adjusted EPS has been reset to at least $5.00 — roughly an 80% cut from the $24.50 starting guide issued February 5, 2025.
- The cyclical case. State Medicaid rate cycles take 12-24 months to catch up to cost trend; the 2017-18 recovery saw consolidated MCR fall from 88.3% to 82.1% in 14 months. Q1 FY2026 operating cash flow swung to +$1.08B from a -$535M FY25 burn.
- The structural case. The lead 10-K risk factor migrated from 'COVID' (FY21) to 'rates paid to us by states may be insufficient to cover our rising medical care costs' (FY25); Q1 FY2026 Medicaid-segment MCR printed 92.0%, higher than the FY25 full-year 91.8%.
- The sensitivity. Every 100 bps of medical-care ratio is worth roughly $430M of pre-tax income on the $43B premium base — about $6 of EPS at the current share count.
Valuation hit a 20-year low while the balance sheet stretched for the first time in five years.
Management spent $1.04B on buybacks in FY2025 — net new debt was $843M, on top of $1.1B of term-loan churn (drawn and repaid during the year), with the standout instrument being $850M of new 6.5% senior notes issued November 2025 — while operating cash flow swung from +$644M to -$535M. The February 4, 2026 credit-agreement amendment temporarily lowered the minimum interest-coverage covenant to 1.75x through year-end, stepping back to 2.75x by Q3 2027. The favorable prior-year reserve cushion that supported FY23-24 earnings has been almost entirely drawn, leaving the FY26 print with little buffer if medical claims develop unfavorably.
Five disciplined years, then a 24-month rupture.
Chapter I (2018-2023). A board-driven shakeup removed the founder family in 2017 and installed a CEO from Aetna and The Hanover. He exited the broken Marketplace book, rolled up seven Medicaid acquisitions at an average 22% of premium, and compounded adjusted EPS to $20.88 by FY2023 with through-cycle ROE of 27-30%.
The break. Industry-wide medical-cost trend ran ahead of state rate-setting starting Q2 2024. Three guidance cuts in six months — $24.50 to $19 to $14 to an $11.03 actual — ended in a covenant relief amendment, a $93M MAPD impairment, and the deliberate retreat of $2.3B of mispriced Marketplace premium.
Today. Q1 FY2026 produced the first clean beat in five quarters; management held the 2029 adjusted-EPS target of $25 at the May 8 Investor Day; a Florida sole-selection ramps in late 2026 and an Illinois Medicaid win was awarded June 10, 2026. The 5-10 year case still hinges on whether two consecutive quarters of consolidated MCR below 90% materialise.
The tape has priced an inflection the fundamentals have not yet confirmed.
- The round trip. From a $420.75 all-time high (March 2024) to a $122.65 52-week low (February 11, 2026) on serial guide cuts, then a +64% rebound to $200.28 — through the $184 average analyst target and a fresh golden cross printed June 2, 2026.
- Short book unwound. Reported short interest peaked at 4.39M shares (8.2% of float) on November 28, 2025 at the lows and has covered to 2.53M (4.9%) by May 29, 2026 — back near the 2.2% pre-shock baseline, with no published short report or activist campaign outstanding.
- Volume tells the other story. The +64% rally has come on declining volume, realized volatility is still 39.6% annualized, and the next earnings print is 38 days out (July 22) — the first chance for the cycle-inflection narrative to be reconfirmed or reversed.
The CEO and CFO are personally named in a federal securities class action.
- Hindlemann v. Molina. Federal securities class action (Case 2:25-cv-09461, Central District of California) names CEO Joseph Zubretsky and CFO Mark Keim personally; class period February 5 - July 23, 2025; amended complaint filed March 31, 2026; motion-to-dismiss ruling expected in 2H 2026.
- Pay-for-performance fired; shareholders unconvinced. 2025 cash bonuses went to zero, three vintages of performance share units forfeited, and CEO 'compensation actually paid' for FY25 was negative $15.3M. Say-on-pay support still collapsed from 90%+ to 40%, rebuking a Fall 2024 retention grant whose $32 EPS hurdle is now expected to vest at zero.
- Buybacks into the shock. $1.5B of repurchases between Q3 2024 and Q1 2025 at an average of roughly $313/share are about 36% underwater at today's price; the FY25 $1.04B program was financed alongside $843M of net new debt (anchored by $850M of 6.5% senior notes issued November 2025) while operating cash flow burned -$535M. COO James Woys bought 10,000 shares at $155.94 on August 4, 2025 (per InsiderTrades/MarketBeat tracking of his Form 4 filing) — the sole executive open-market purchase of the cycle alongside director Richard Zoretic's 800-share buy on February 12, 2026.
Both sides have named the same line: prior-year reserve development.
- For the cycle thesis. Valuation at a 20-year low (0.11x EV/Revenue, ~8x normalized EPS); cost discipline survived the same shock that broke Centene (-$6.4B LTM net loss); Q1 FY26 operating cash reversal of +$1.08B; the 2017-18 cycle proved that state rate catch-up works on a 12-24 month lag.
- Against the cycle thesis. The 10-K itself questions rate adequacy; the credit-agreement covenant was relieved by lenders in February 2026; the favorable reserve cushion has collapsed from $675M to $98M; Q1 FY26 Medicaid-segment MCR moved the wrong way to 92.0%.
- What flips it. Favorable prior-year reserve development of $200M+ in the Q1 or Q2 FY26 medical-claims-payable rollforward, plus Medicaid-segment MCR below 91% by Q3, would validate the cycle. Unfavorable PYD in either quarter, or a California Medi-Cal 2027 RFP loss, would end the case.
Watchlist to re-rate: Q2 FY26 reserve-development line (releases after the close on July 22, 2026); Medicaid-segment MCR cadence through year-end; California Medi-Cal 2027 RFP award timing.